Vericel director Zerbe exercises options, sells 2,000 shares

Q: How many VCEL shares did Robert L. Md Zerbe sell, and at what price?

Robert L. Md Zerbe sold 2,000 VCEL common shares at $57.88 per share on November 9, 2026. The sale was effected automatically under a Rule 10b5-1 trading plan he adopted on May 19, 2026.

Q: How many VCEL options did director Robert L. Md Zerbe exercise?

Robert L. Md Zerbe exercised options covering 2,000 common shares at an exercise price of $13.05 per share on November 9, 2026. The options were originally granted May 2, 2018, and became exercisable in equal monthly installments over one year, contingent upon continued service.

Available on EDGAR 11/12/2026 - 07:44 PM EST Accepted by SEC EDGAR 11/12/2026 - 07:43 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Vericel Corp director Robert L. Md Zerbe exercised options covering 2,000 common shares on November 9, 2026, at an exercise price of $13.05 per share, then sold 2,000 shares at $57.88 per share. The sale was effected automatically under a Rule 10b5-1 trading plan adopted May 19, 2026. The options were originally granted May 2, 2018, and became exercisable in equal monthly installments over one year, contingent upon continued service to the company.

Insider Trade Summary 10b5-1

Exercise and Sale: 2,000 shares ($90K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider ZERBE ROBERT L MD

Role Director

Sold 2,000 shs ($116K)

Approx. gross sale proceeds $116K

Approx. exercise cost $26K

Approx. pre-tax spread $90K

Share of Position Sold 5.7%

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) ^F2	2,000	$0.00	$0.00
Exercise	Common Stock	2,000	$13.05	$26K
Sale	Common Stock ^F1	2,000	$57.88	$116K

Holdings After Transaction: Stock Option (Right to Buy) — 0 options (Direct); Common Stock — 32,995 shares (Direct)

Holdings Before and After: Common Stock, 32,995 to 32,995 shares (Direct)

Other Insiders: 3 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

F1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2026.
F2. These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 2, 2018, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company.

Key Figures

Options exercised: 2,000 shares Exercise price: $13.05 per share Shares sold: 2,000 shares +1 more

4 metrics

Options exercised 2,000 shares November 9, 2026

Exercise price $13.05 per share Options exercised November 9, 2026

Shares sold 2,000 shares November 9, 2026

Sale price $57.88 per share Automatic sale on November 9, 2026

Key Terms

Rule 10b5-1 trading plan, exercise price

2 terms

Rule 10b5-1 trading plan regulatory

"automatic sale pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

exercise price financial

"conversion or exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many VCEL shares did Robert L. Md Zerbe sell, and at what price?

Robert L. Md Zerbe sold 2,000 VCEL common shares at $57.88 per share on November 9, 2026. The sale was effected automatically under a Rule 10b5-1 trading plan he adopted on May 19, 2026.

How many VCEL options did director Robert L. Md Zerbe exercise?

Robert L. Md Zerbe exercised options covering 2,000 common shares at an exercise price of $13.05 per share on November 9, 2026. The options were originally granted May 2, 2018, and became exercisable in equal monthly installments over one year, contingent upon continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ZERBE ROBERT L MD

(Last)

(First)

(Middle)

C/O VERICEL CORPORATION

25 BLUE SKY DRIVE

(Street)

BURLINGTON

MASSACHUSETTS

01803

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vericel Corp [ VCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/09/2026		M		2,000	A	$13.05	34,995	D
Common Stock	11/09/2026		S		2,000	D⁽¹⁾	$57.88	32,995	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$13.05	11/09/2026		M		2,000		⁽²⁾	05/02/2028	Common Stock	2,000	$0	0	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2026.

2. These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 2, 2018, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company.

	/s/ Sean Flynn, as Attorney-in-Fact for Robert Zerbe	11/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR